Episode Details

FDA just approved a groundbreaking daily pill, Rasonque, for adults with advanced pancreatic cancer — a disease that’s historically been nearly impossible to treat. Targeting the RAS protein that fuels tumor growth, this drug gave patients an average survival of 13.2 months — more than double the 6.7 months seen with standard chemo. With 67,000 new cases annually in the U.S., this approval offers new hope for those who’ve exhausted other options. The FDA fast-tracked it, delivering it six months early, and even let some patients access it before full approval. Side effects like rash, diarrhea, and fatigue are possible, but many may see it as a necessary trade-off for extended life.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6beec924e8df9efa